Clarius Mobile Health Achieves Significant Milestones
Clarius Mobile Health, a prominent player in the realm of AI-enhanced handheld ultrasound technology, has successfully turned a corner in its journey, marking 2025 as a historic year. This achievement includes reaching profitability and experiencing an impressive revenue growth rate of 20% compared to the previous year. This transformative success not only underscores Clarius's effective business model but also solidifies its position as a trailblazer in the competitive medical imaging landscape.
AI Leadership and Clinical Validation
According to CEO Laurent Pelissier, the year 2025 has been crucial, emphasizing the company's focus on clinical innovation coupled with operational excellence. He stated, 'Achieving profitability while simultaneously launching FDA-cleared AI models indicates that Clarius is not merely on a growth trajectory; we are fortifying the future of handheld ultrasound for sustained market relevance.'
Clarius's prominence in the field of AI is further cemented by the launch of two new FDA-cleared AI models. This brings the total number of FDA-cleared models to six, while the number of AI technologies deployed increases to sixteen. The Clarius Prostate AI model is designed to identify the prostate automatically and measure PSA Density for urological assessments, while the Clarius Median Nerve AI assists in locating the median nerve effectively during evaluations connected to Carpal Tunnel Syndrome.
Global Recognition and Expansion Efforts
This year, Clarius's innovative approach to medical imaging garnered international recognition. The company was celebrated as one of TIME's 'World's Top HealthTech Companies of 2025,' achieving a top-tier ranking in the Medical Devices & Wearables category. Clarius didn't stop there; its distribution network expansion now caters to over 70 countries, doubling growth in the rapidly developing Indo-Pacific regions. Additionally, Clarius proudly participated among a select few companies chosen for Canada's Global Hypergrowth Program.
Strategic Collaborations and Product Innovations
In 2025, Clarius also broadened its business ecosystem by forming strategic partnerships that opened new revenue channels. By establishing its ultrasound scanners as essential tools in clinical trials through collaborations with pharmaceutical companies and Contract Research Organizations (CROs), Clarius is reinforcing its commitment to advancing healthcare technology.
The company introduced over 60 new features across four major software updates this year, including enhancing T-Mode™ capabilities for various scanning applications such as breast, shoulder, and abdominal. This move is part of Clarius’s strategy to provide innovative solutions to diverse medical fields, now even extending into veterinary medicine with the Auto Preset AI feature.
Community Engagement and Educational Commitment
Clarius took significant strides in community engagement by participating in over 80 medical tradeshows internationally, coupled with hosting 15 clinical webinars directed towards healthcare practitioners. This not only reinforces its role as an industry leader but also enhances its educational outreach by forming connections with 29 educational organizations worldwide, thus promoting ultrasound education and accessibility across the medical field.
Future Aspirations
Looking forward to 2026, Clarius aims to amplify its AI capabilities while pursuing deeper partnerships in the industry. The objective is to ensure affordable, efficient, and high-quality ultrasound technology is accessible to healthcare providers across the globe. This ongoing commitment promises to revolutionize patient care and improve clinical outcomes significantly.
About Clarius Mobile Health
Clarius is dedicated to delivering accurate, user-friendly, and financially accessible ultrasound solutions to medical professionals in all specialties. With decades of experience in medical imaging, Clarius understands that superior ultrasound imaging is crucial for enhancing both confidence and patient care. Currently, its AI-powered handheld wireless ultrasound scanners seamlessly connect to iOS and Android devices, providing high-resolution images typically only found in more expensive, bulky systems. Having completed nearly 7 million high-definition scans with its handheld scanners, Clarius's technology is now available in over 70 countries.
Frequently Asked Questions
What achievements did Clarius Mobile Health reach in 2025?
Clarius Mobile Health achieved significant profitability and a 20% revenue growth rate, along with new FDA-cleared AI models.
How has Clarius contributed to the advancement of medical imaging?
Clarius has launched multiple FDA-cleared AI models and expanded its technology's applications, solidifying its leadership in the POCUS sector.
What recognition has Clarius received globally?
The company was named one of TIME's 'World's Top HealthTech Companies of 2025,' highlighting its leadership in the medical devices sector.
What are Clarius’s plans for the future?
Clarius aims to expand its AI capabilities and deepen industry partnerships, ensuring wider access to high-quality ultrasound technology.
How does Clarius support community engagement?
Clarius participated in numerous medical tradeshows and hosted educational webinars, enhancing community outreach and ultrasound education.
